In the pathogenesis of psoriasis, systemic inflammation and oxidative stress play mutual roles interrelated with metabolic syndrome (MetS). This study aims to map the selected markers of inflammation (C-reactive protein (CRP)), oxidative damage to nucleic acids (DNA/RNA damage; 8-hydroxy-2'-deoxyguanosine, 8-hydroxyguanosine, and 8-hydroxyguanine), and the parameters of MetS (waist circumference, fasting glucose, triglycerides, high-density lipoprotein (HDL) cholesterol, diastolic and systolic blood pressure) in a group of 37 patients with psoriasis (62% of MetS) and in 43 healthy controls (42% of MetS). Levels of CRP, DNA/RNA damage, fasting glucose, and triglycerides were significantly elevated in patients. MetS in conjunction with psoriasis was associated with high levels of CRP, significantly higher than in control subjects without MetS. Patients with MetS exhibited further DNA/RNA damage, which was significantly higher in comparison with the control group. Our study supports the independent role of psoriasis and MetS in the increase of CRP and DNA/RNA damage. The psoriasis contributes to an increase in the levels of both effects more significantly than MetS. The psoriasis also diminished the relationship between CRP and oxidative damage to nucleic acids existent in controls.

Clinic of Dermal and Venereal Diseases Charles University Hospital Hradec Kralove 500 05 Hradec Kralove Czech Republic

Department of Clinical Immunology and Allergology Charles University Faculty of Medicine in Hradec Kralove 500 03 Hradec Kralove Czech Republic

Department of Hygiene and Preventive Medicine Charles University Faculty of Medicine in Hradec Kralove 500 03 Hradec Kralove Czech Republic

Department of Pathological Physiology Charles University Faculty of Medicine in Hradec Kralove 500 03 Hradec Kralove Czech Republic

Department of Transfusion Medicine Charles University Hospital in Hradec Kralove 500 05 Hradec Kralove Czech Republic

Institute of Clinical Biochemistry and Diagnostics Charles University Hospital and Faculty of Medicine in Hradec Kralove 500 05 Hradec Kralove Czech Republic

Zobrazit více v PubMed

Milic M., Frustaci A., del Bufalo A., Sanchez-Alarcon J., Valencia-Quintana R., Russo P., Bonassi S. DNA damage in non-communicable diseases: A clinical and epidemiological perspective. Mutat. Res. 2015;776:118–127. doi: 10.1016/j.mrfmmm.2014.11.009. PubMed DOI

Michalek I.M., Loring B., John S.M. A systematic review of worldwide epidemiology of psoriasis. J. Eur. Acad. Dermatol. Venereol. 2017;31:205–212. doi: 10.1111/jdv.13854. PubMed DOI

Love T.J., Qureshi A.A., Karlson E.W., Gelfand J.M., Choi H.K. Prevalence of the metabolic syndrome in psoriasis: Results from the National Health and Nutrition Examination Survey, 2003–2006. Arch. Dermatol. 2011;147:419–424. doi: 10.1001/archdermatol.2010.370. PubMed DOI PMC

Vachatova S., Andrys C., Krejsek J., Salavec M., Ettler K., Rehacek V., Cermakova E., Malkova A., Fiala Z., Borska L. Metabolic Syndrome and Selective Inflammatory Markers in Psoriatic Patients. J. Immunol. Res. 2016;2016:8. doi: 10.1155/2016/5380792. PubMed DOI PMC

Takahashi H., Iinuma S., Honma M., Iizuka H. Increased serum C-reactive protein level in Japanese patients of psoriasis with cardio- and cerebrovascular disease. J. Dermatol. 2014;41:981–985. doi: 10.1111/1346-8138.12632. PubMed DOI

Vadakayil A.R., Dandekeri S., Kambil S.M., Ali N.M. Role of C-reactive protein as a marker of disease severity and cardiovascular risk in patients with psoriasis. Indian Dermatol. Online J. 2015;6:322–325. doi: 10.4103/2229-5178.164483. PubMed DOI PMC

Coimbra S., Oliveira H., Reis F., Belo L., Rocha S., Quintanilha A., Figueiredo A., Teixeira F., Castro E., Rocha-Pereira P., et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J. Eur. Acad. Dermatol. Venereol. 2010;24:789–796. doi: 10.1111/j.1468-3083.2009.03527.x. PubMed DOI

Beygi S., Lajevardi V., Abedini R. C-reactive protein in psoriasis: A review of the literature. J. Eur. Acad. Dermatol. Venereol. 2014;28:700–711. doi: 10.1111/jdv.12257. PubMed DOI

Ridker P.M., Buring J.E., Cook N.R., Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14,719 initially healthy American women. Circulation. 2003;107:391–397. doi: 10.1161/01.CIR.0000055014.62083.05. PubMed DOI

Meyer M.R., Barton M. GPER blockers as Nox downregulators: A new drug class to target chronic non-communicable diseases. J. Steroid Biochem. Mol. Biol. 2017 doi: 10.1016/j.jsbmb.2017.03.019. PubMed DOI

Rogulj D., El Aklouk I., Konjevoda P., Ljubic S., Pibernik Okanovic M., Barbir A., Luburic M., Radman M., Budinski N., Vucic Lovrencic M. Age-dependent systemic DNA damage in early Type 2 Diabetes mellitus. Acta Biochim. Pol. 2017;64:233–238. doi: 10.18388/abp.2016_1313. PubMed DOI

Mantha A.K., Sarkar B., Tell G. A short review on the implications of base excision repair pathway for neurons: Relevance to neurodegenerative diseases. Mitochondrion. 2014;16:38–49. doi: 10.1016/j.mito.2013.10.007. PubMed DOI

Nordholm D., Poulsen H.E., Hjorthoj C., Randers L., Nielsen M.O., Wulff S., Krakauer K., Norbak-Emig H., Henriksen T., Glenthoj B., et al. Systemic oxidative DNA and RNA damage are not increased during early phases of psychosis: A case control study. Psychiatry Res. 2016;241:201–206. doi: 10.1016/j.psychres.2016.04.062. PubMed DOI

Borska L., Andrys C., Krejsek J., Palicka V., Vorisek V., Hamakova K., Kremlacek J., Borsky P., Fiala Z. Influence of dermal exposure to ultraviolet radiation and coal tar (polycyclic aromatic hydrocarbons) on the skin aging process. J. Dermatol. Sci. 2016;81:192–202. doi: 10.1016/j.jdermsci.2015.12.010. PubMed DOI

Basavaraj K.H., Vasu Devaraju P., Rao K.S. Studies on serum 8-hydroxy guanosine (8-OHdG) as reliable biomarker for psoriasis. J. Eur. Acad. Dermatol. Venereol. 2013;27:655–657. doi: 10.1111/j.1468-3083.2011.04441.x. PubMed DOI

Kojanova M., Fialova J., Cetkovska P., Gkalpakiotis S., Jircikova J., Dolezal T., Arenberger P. Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries. Int. J. Dermatol. 2017;56:428–434. doi: 10.1111/ijd.13543. PubMed DOI

Correa M.M., Thume E., De Oliveira E.R., Tomasi E. Performance of the waist-to-height ratio in identifying obesity and predicting non-communicable diseases in the elderly population: A systematic literature review. Arch. Gerontol. Geriatr. 2016;65:174–182. doi: 10.1016/j.archger.2016.03.021. PubMed DOI

Ricci G., Pirillo I., Tomassoni D., Sirignano A., Grappasonni I. Metabolic syndrome, hypertension, and nervous system injury: Epidemiological correlates. Clin. Exp. Hypertens. 2017;39:8–16. doi: 10.1080/10641963.2016.1210629. PubMed DOI

Milcic D., Jankovic S., Vesic S., Milinkovic M., Marinkovic J., Cirkovic A., Jankovic J. Prevalence of metabolic syndrome in patients with psoriasis: A hospital-based cross-sectional study. Anais Brasileiros de Dermatologia. 2017;92:46–51. doi: 10.1590/abd1806-4841.20175178. PubMed DOI PMC

Sudhesan A., Rajappa M., Chandrashekar L., Ananthanarayanan P.H., Thappa D.M., Satheesh S., Chandrasekaran A., Devaraju P. Association of C-Reactive Protein (rs1205) Gene Polymorphism with Susceptibility to Psoriasis in South Indian Tamils. J. Clin. Diagn. Res. 2016;10:Gc01–Gc04. doi: 10.7860/JCDR/2016/23391.8624. PubMed DOI PMC

Armstrong A.W., Harskamp C.T., Armstrong E.J. Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies. J. Am. Acad. Dermatol. 2013;68:654–662. doi: 10.1016/j.jaad.2012.08.015. PubMed DOI

Alsufyani M.A., Golant A.K., Lebwohl M. Psoriasis and the metabolic syndrome. Dermatol. Ther. 2010;23:137–143. doi: 10.1111/j.1529-8019.2010.01307.x. PubMed DOI

Langan S.M., Seminara N.M., Shin D.B., Troxel A.B., Kimmel S.E., Mehta N.N., Margolis D.J., Gelfand J.M. Prevalence of metabolic syndrome in patients with psoriasis: A population-based study in the United Kingdom. J. Investig. Dermatol. 2012;132:556–562. doi: 10.1038/jid.2011.365. PubMed DOI PMC

Miller I.M., Ellervik C., Zarchi K., Ibler K.S., Vinding G.R., Knudsen K.M., Jemec G.B. The association of metabolic syndrome and psoriasis: A population- and hospital-based cross-sectional study. J. Eur. Acad. Dermatol. Venereol. 2015;29:490–497. doi: 10.1111/jdv.12595. PubMed DOI

Barrea L., Nappi F., Di Somma C., Savanelli M.C., Falco A., Balato A., Balato N., Savastano S. Environmental Risk Factors in Psoriasis: The Point of View of the Nutritionist. Int. J. Environ. Res. Public Health. 2016;13 doi: 10.3390/ijerph13070743. PubMed DOI PMC

Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B., Gelfand J.M. Prevalence of cardiovascular risk factors in patients with psoriasis. J. Am. Acad. Dermatol. 2006;55:829–835. doi: 10.1016/j.jaad.2006.08.040. PubMed DOI

Taheri Sarvtin M., Hedayati M.T., Shokohi T., HajHeydari Z. Serum lipids and lipoproteins in patients with psoriasis. Arch. Iran. Med. 2014;17:343–346. PubMed

Takahashi H., Iizuka H. Psoriasis and metabolic syndrome. J. Dermatol. 2012;39:212–218. doi: 10.1111/j.1346-8138.2011.01408.x. PubMed DOI

Akhyani M., Ehsani A.H., Robati R.M., Robati A.M. The lipid profile in psoriasis: A controlled study. J. Eur. Acad. Dermatol. Venereol. 2007;21:1330–1332. doi: 10.1111/j.1468-3083.2007.02260.x. PubMed DOI

Mallbris L., Granath F., Hamsten A., Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J. Am. Acad. Dermatol. 2006;54:614–621. doi: 10.1016/j.jaad.2005.11.1079. PubMed DOI

Lin X., Huang T. Oxidative stress in psoriasis and potential therapeutic use of antioxidants. Free Radic. Res. 2016;50:585–595. doi: 10.3109/10715762.2016.1162301. PubMed DOI

Borska L., Andrys C., Krejsek J., Palicka V., Chmelarova M., Hamakova K., Kremlacek J., Fiala Z. Oxidative Damage to Nucleic Acids and Benzo(a)pyrene-7,8-diol-9,10-epoxide-DNA Adducts and Chromosomal Aberration in Children with Psoriasis Repeatedly Exposed to Crude Coal Tar Ointment and UV Radiation. Oxid. Med. Cell. Longev. 2014;2014:302528. doi: 10.1155/2014/302528. PubMed DOI PMC

National Institutes of Health. National Heart, Lung, and Blood Institute. National Cholesterol Education Program Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421. PubMed

Salihbegovic E.M., Hadzigrahic N., Cickusic A.J. Psoriasis and metabolic syndrome. Med. Arch. 2015;69:85–87. doi: 10.5455/medarh.2015.69.85-87. PubMed DOI PMC

R Core Team . R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; Vienna, Austria: 2017. Version 3.4. Available online: https://www.R-project.org/

Gross J., Ligges U. [(accessed on 15 September 2017)];Nortest: Tests for Normality. 2015 R Package Version 1.0-4. Available online: https://CRAN.R-project.org/package=nortest.

Diedenhofen B., Musch J. cocor: A comprehensive solution for the statistical comparison of correlations. PLoS ONE. 2015;10:e0121945. doi: 10.1371/journal.pone.0121945. PubMed DOI PMC

The Influence of Metabolic Syndrome on Potential Aging Biomarkers in Participants with Metabolic Syndrome Compared to Healthy Controls

Evaluation of potential aging biomarkers in healthy individuals: telomerase, AGEs, GDF11/15, sirtuin 1, NAD+, NLRP3, DNA/RNA damage, and klotho

Telomere length, oxidative and epigenetic changes in blood DNA of patients with exacerbated psoriasis vulgaris

The Presence of Psoriasis, Metabolic Syndrome and Their Combination Increases the Serum Levels of CRP and CD5L but Not sCD200R1 and sTLR2 in Participants

Chromosomal Aberrations and Oxidative Stress in Psoriatic Patients with and without Metabolic Syndrome

Significantly Altered Serum Levels of NAD, AGE, RAGE, CRP, and Elastin as Potential Biomarkers of Psoriasis and Aging-A Case-Control Study

Metabolic Syndrome, Clusterin and Elafin in Patients with Psoriasis Vulgaris

The Impact of Psoriasis and Metabolic Syndrome on the Systemic Inflammation and Oxidative Damage to Nucleic Acids

Alarmins HMGB1, IL-33, S100A7, and S100A12 in Psoriasis Vulgaris

Goeckerman Therapy of Psoriasis: Genotoxicity, Dietary Micronutrients, Homocysteine, and MTHFR Gene Polymorphisms